| Document |
Document Title |
|
WO/2002/096855A2 |
In a preferred embodiment, the subject invention concerns novel analogs of oxybutynin. The present invention also concerns methods for synthesizing the oxybutynin analogs of the present invention. The invention also pertains to methods f...
|
|
WO/2002/096423A2 |
The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a PDEIV inhibitor that is therapeutically effective in the treatment of sa...
|
|
WO/2002/094273A2 |
A combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (i) an adenosine A2 receptor agonist; and (ii) an anti-cholinergic agent, preferably comprising a member select...
|
|
WO/2002/094790A1 |
A fused heterocyclic compound represented by the general formula (I): (I) (wherein the symbols are the same as defined in the description), optically active isomer thereof, pharmaceutically acceptable salt of any of these, hydrate of any...
|
|
WO/2002/089806A1 |
Diazabicyclo[3.3.1]nonane derivatives that inhibit the peptidyl-prolyl isomerase enzyme activity associated with FK-506 binding proteins (FKBP) are described for treating neurological disorders. Also described are compounds useful for pr...
|
|
WO/2002/085900A1 |
Compounds of the formula (I) are useful for treating the cognitive deficits due to aging, stroke, head trauma, Alzheimer's disease or other neurodegenerative diseases, or schizophrenia and also treatment of disorders related to excessive...
|
|
WO/2002/086427A1 |
There is provided a method for metering a quantity of a particulate material onto the surface of a porous retainer comprising the steps of: exposing a first surface of a porous retainer to a pool of particulate material; applying a vacuu...
|
|
WO/2002/083669A1 |
Compounds and methods of modulating the activity of P-glycoproteins are disclosed. The method utilizes compounds derived from Erythroxylum pervillei. the compounds overcome multidrug resistance and can be used therapeutically to enhance ...
|
|
WO/2002/081453A1 |
The invention concerns compounds derived from 2-thiohydantoin selected among compounds of general formula (I), such as defined in the claims, and their addition salts with an acid, in particular pharmaceutically acceptable salts. The inv...
|
|
WO/2002/081448A1 |
A benzamidine derivative having the general formula: (1) wherein R?1¿ represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group, R?2¿ represents a hydrogen atom or a halogen atom, R?3¿ represents a hydrogen atom, ...
|
|
WO/2002/079151A1 |
Compounds of the formula (I) are antagonists of the chemokine MCP-1 (CCR2B) receptor and are of use in treating in inflammatory conditions with monocyte and/or lymphocyte involvement.
|
|
WO/2002/079190A1 |
A compound of the formula (I): in which: R?1¿ is (C¿1-6?)alkyl, optionally substituted aryl or optionally substituted heteroaryl; R?2¿ and R?3¿ which may be the same or different are selected from the group consisting of hydrogen, ha...
|
|
WO/2002/072570A2 |
Disclosed are novel compounds of the formula (I). Also disclosed are pharmaceutical compositions comprising the compounds of Formula (I). Also disclosed are methods of treating various diseases or conditions, such as, for example, allerg...
|
|
WO/2002/072095A2 |
The invention relates to the use of (1$g(a),2$g(b),4$g(b),5$g(a),7$g(b))-7-[(hydroxydi-2-thienyl
acetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02.4] nonane salts for producing a medicament used in the prevention and treatment of ...
|
|
WO/2002/068388A2 |
Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the t...
|
|
WO/2002/068377A1 |
(R) -2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treat...
|
|
WO/2002/068409A1 |
Compounds represented by Formula (I): (I)or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
|
|
WO/2002/066446A1 |
The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D¿3? receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associa...
|
|
WO/2002/066468A2 |
The invention relates to heterocyclic substituted urea derivatives of the formula (I) that display selective binding to dopamine D¿3? receptors. In another aspect, the invention relates to a method for treating central nervous system di...
|
|
WO/2002/066469A2 |
The invention relates to heterocyclic substituted amide derivatives of formula (I) that display selective binding to dopamine D¿3? receptors. In another aspect, the invention relates to a method for treating central nervous system disor...
|
|
WO/2002/064128A1 |
The invention relates to the use of a compound that modulates the association of caspase-9 to Apaf-1 for the treatment of diseases characterized by excessive or insufficient cell death.
|
|
WO/2002/062788A1 |
Compounds possessing 5HT7 activity of formula (I) or a pharmaceutically acceptable salt thereof are disclosed (Formula I), in which X is a 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitroxygen a...
|
|
WO/2002/062324A2 |
Smooth muscle one modulators are applied topically to treat oesophageal motility disorders and gastro-oesophageal reflux disease. Topical application of the smooth muscle tone modulators reduces the risk of the unwanted side-effects obse...
|
|
WO/2002/057262A2 |
A compound of Formula (I) wherein A is-CH2-CH2- or -CH=CH-; R2 is hydrogen, CHO, COOC1-C10 alkyl, optionally substituted C2-C10 alkyl, substituted methyl, optionally substituted C1-C10 alkoxy, optionally substituted C2-C10 alkenyloxy, op...
|
|
WO/2002/057263A1 |
A compound of formula (I): wherein A is-CH¿2?-CH¿2?-or-CH=CH-; R?2¿ is hydrogen, CHO, COOC¿1?-C¿10? alkyl, optionally substituted C¿2?-C¿10? alkyl, substituted methyl, optionally substituted C¿1-?C¿10? alkoxy, optionally substit...
|
|
WO/2002/057254A1 |
Compositions for prevention or treatment of hepatopathy, containing as the active ingredient compounds represented by the general formula (I), or pharmaceutically acceptable salts, ester, or other derivatives thereof: (I) wherein A is a ...
|
|
WO2001040188A9 |
The present invention is directed to curcumin analogs (I), wherein Y is OH, halogen, or CF3; Z is H, OH, OR1, halogen, or CF3; X1 and X2 are independently C or N; and A is as defined in the application; exhibiting anti-tumor and anti-ang...
|
|
WO/2002/051808A2 |
Amide derivatives of 1,4 di-substituted piperidine compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein R?1¿ is optionally substituted cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or hete...
|
|
WO/2002/051840A1 |
The invention relates to a novel method for producing (1$g(a), 2$g(b), 4$g(b), 5$g(a), 7$g(b))-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-ox
a-9-azoniatricyclo[3.3.1.0?2,4-¿] nonane bromide.
|
|
WO2002004442A9 |
Pharmaceutical compositions incorporate compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the cen...
|
|
WO/2002/044175A2 |
The present invention provides a compound for chelating a metal or a metal complex, characterized in that it consists of a bis-dithiocarbamate structure (F) having the formula below: (formule chimique ô insérer ici)in which n and m are...
|
|
WO/2002/036106A2 |
The invention relates to novel medicament compositions based on anticholinergics and corticosteroids, a method for the production thereof and the use thereof for treating respiratory conditions.
|
|
WO/2002/036591A2 |
The invention relates to a propellant-free inhalation formulation of tiotropium bromide or tiotropium bromide monohydrate, which is dissolved in water or in a mixture consisting of water and ethanol, and to propellant-free inhalable aero...
|
|
WO/2002/034736A1 |
A method of synthesis of a bicyclic or polycyclic compound of formula (I) or formula (II) in which: E represents an electrophile; each of R, R1, R2, R3, R6, R7, R8, R9 and X independently represents the common organic substituent groups ...
|
|
WO/2002/032901A2 |
A compound of the formula (I) or the pharmaceutically acceptable salt thereof; wherein a, c, d, k, l, m, W, X, Y Z, R?1¿, and R?4¿ are as defined, and useful to treat inflammation and other immune disorders.
|
|
WO/2002/032899A1 |
The invention relates to novel anticholinergic agents of general formula (1), wherein A, X?-¿ and radicals R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿ and R?7¿ can have the meanings as cited in the claims and in the description. The inven...
|
|
WO/2002/032898A2 |
The invention relates to novel anticholinergics of general formula (1) wherein A, X?-¿ and the radical R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿, R?7¿ and R?8¿ can have the meaning as cited in the claims and the description. The invent...
|
|
WO/2002/030405A2 |
This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoaminergic substance for the treatment of affective disorders, as well as to pharmaceutical compositions comprising these substan...
|
|
WO/2002/030390A2 |
The invention relates to a novel method for producing powdery preparations which can be inhaled.
|
|
WO/2002/030928A1 |
The invention relates to a crystalline monohydrate of (1$g(a),2$g(b),4$g(b),5$g(a),7$g(b))-7-[(hydroxydi-2-thienyl
acetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatrycyclo[3.3.1.0?2,4Â
¿]nonane bromide, to a method for producing the same, and to ...
|
|
WO/2002/030389A1 |
The invention relates to tiotropium-containing powdery preparations to be inhaled, to methods for producing them and to the use thereof in the production of medicaments for treating respiratory diseases, especially for treating COPD (chr...
|
|
WO/2002/024636A2 |
N-Benzoyl arylsulfonamides having the formula (I) are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
|
|
WO/2002/016340A1 |
The invention concerns aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives of general formula (1). Said compounds are useful as medicines in particular for treating pathological syndromes of the cardiovascular system.
|
|
WO/2002/016339A1 |
The invention concerns novel benzofuran or benzothiophene derivatives of general formula (I). Said compounds are useful as medicines in particular for treating pathological syndromes of the cardiovascular system.
|
|
WO/2002/014273A1 |
The invention relates to novel cinnamide compounds which have 5-HT¿2C? antagonist activity and have the general formula (I), or is a pharmaceutically acceptable salt thereof: in which P is phenyl or naphthyl; R?1¿ is halogen, C¿1-6?al...
|
|
WO/2002/012235A1 |
The present invention relates to compounds of formula (I) wherein each A is independently halo; Y is (CH¿2?)m-, -C(O)- or S(O)-; R?1¿ and R?2¿ are independently C¿1-4? alkyl; R?3¿ is substituted azacycloalkyl etc.; R?4¿ is phenyl s...
|
|
WO/2002/004402A1 |
Compounds of the general formula (|), which exhibit selective muscarinic M¿3? receptor antagonism, little have side effects, and are suitable for administration by inhalation and useful as therapeutic agents for respiratory system disea...
|
|
WO/2001/090716A2 |
This invention generally relates to nanocrystal compounds, and linker arm for nanocrystal compounds that attach the nanocrystals to the organic compounds. The nanocrystal compound comprises a nanocrystal, linker arm, and organic compound...
|
|
WO/2001/090717A2 |
This invention generally relates to nanocrystal compounds, and linker arm for nanocrystal compounds that attach the nanocrystals to the organic compounds. The nanocrystal compound comprises a nanocrystal, linker arm, and organic compound...
|
|
WO/2001/090106A2 |
The present invention provides compounds of the formula (I): wherein R?1¿ is C¿3-6? cycloalkyl optionally substituted by one or more fluorine atoms, or C¿1-6? alkyl optionally substituted by one or more fluorine atoms, or C¿3-6? cycl...
|
